查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1613242

皮肤 T 细胞淋巴瘤市场：按适应症、治疗、产品和最终用户划分 - 全球预测 2025-2030

Cutaneous T-Cell-Lymphoma Market (CTCL) by Indication (Mycosis Fungoides, Sezary Syndrome), Treatment (Biological Therapies, Phototherapy, Radiation Therapy), Product, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年皮肤T细胞淋巴瘤市值为4.1677亿美元，预计到2024年将达到4.3244亿美元，复合年增长率为3.91%，预计到2030年将达到5.4549亿美元。

皮肤 T 细胞淋巴瘤 (CTCL) 是一种罕见的非何杰金氏淋巴瘤，主要影响皮肤，其特征是 T 细胞增殖不受控制。 CTCL 有多种形式，其中最常见的是蕈状肉芽肿和塞札里症候群。研究这个市场的必要性源自于 CTCL 的复杂生物学性质，这需要创新的诊断和治疗方法。这项研究将有助于开发新的治疗方法、改善诊断并帮助医疗保健提供者优化患者照护。市场洞察的应用扩展到製药公司、研究机构和临床环境，以改善治疗通讯协定并创建经济可行的医疗解决方案。最终用途范围包括医疗机构、实验室和专注于罕见癌症进展的教育机构。推动市场成长的主要因素是生技药品、单株抗体的进步以及 CTCL 盛行率的增加。此外，意识的提高和医疗保健基础设施的改善正在加强市场轨迹。由于该疾病的多样性，标靶治疗和个人化医疗的发展存在重大机会，利用政府对孤儿药开发的支持将加速市场开拓。建议包括投资于早期检测的生物标记研究，以及促进策略合作以开发创新药物管道。然而，市场成长受到治疗成本高和患者数量有限等限制，这可能会减缓投资收益。此外，鑑别诊断的复杂性和抗治疗性也是主要问题。克服这些障碍需要专注于精准医学和适应性临床试验设计。创新领域包括利用人工智慧进行预测分析、探索基因治疗的潜力以及利用 CTCL 临床试验环境中的真实世界证据。这个市场的利基但稳定扩张的性质需要持续的研究和多学科方法来有效解决未满足的医疗需求。

主要市场统计
基准年[2023] 41677万美元
预计年份 [2024] 4.3244亿美元
预测年份 [2030] 5.4549亿美元
复合年增长率（%） 3.91%

市场动态：快速发展的皮肤 T 细胞淋巴瘤市场的关键市场洞察

供需的动态交互作用正在改变皮肤 T 细胞淋巴瘤市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 皮肤 T 细胞淋巴瘤的盛行率和认识不断提高
    • 加速核准流程和奖励的监管支援政策
  • 市场限制因素
    • 由于误诊和延误诊断导致治疗费用上升
  • 市场机会
    • 扩大临床试验和合作研究
    • 扩大标靶治疗和免疫疗法的发展
  • 市场挑战
    • 与治疗相关的技术和表现问题

波特五力：开拓皮肤 T 细胞淋巴瘤市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解皮肤 T 细胞淋巴瘤市场的外部影响

外部宏观环境因素在塑造皮肤 T 细胞淋巴瘤市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解皮肤 T 细胞淋巴瘤市场的竞争格局

皮肤 T 细胞淋巴瘤市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位基质皮肤 T 细胞淋巴瘤市场供应商的绩效评估

FPNV定位矩阵是评估皮肤T细胞淋巴瘤市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製皮肤 T 细胞淋巴瘤市场的成功之路

皮肤 T 细胞淋巴瘤市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 提高皮肤 T 细胞淋巴瘤的盛行率和认识
      • 支持快速核准流程和奖励的监管政策
    • 抑制因素
      • 治疗费用上升、误诊和延误诊断
    • 机会
      • 扩大临床试验和合作研究工作
      • 标靶治疗和免疫治疗的进展
    • 任务
      • 与治疗相关的技术和性能问题；
  • 市场区隔分析
    • 适应症：蕈状肉芽肿病例正快速增加，需要局部和全身性治疗。
    • 最终使用者：更多地使用在 CTCL 的特定治疗和个人化护理方面提供广泛专业知识的诊所
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章按适应症分類的皮肤 T 细胞淋巴瘤市场

  • 蕈状肉芽肿
  • Sezary症候群

第七章皮肤T细胞淋巴瘤市场（依治疗）

  • 生物疗法
  • 照光治疗
  • 放射治疗
  • 局部治疗

第 8 章皮肤 T 细胞淋巴瘤市场：副产品

  • 成像技术
  • 分子诊断
  • 照光治疗设备
  • 治疗药物
    • 化疗
    • 免疫调节剂
    • 标靶治疗

第 9 章皮肤 T 细胞淋巴瘤市场：依最终用户分类

  • 门诊手术中心
  • 皮肤科诊所
  • 家庭护理设置
  • 医院
  • 研究中心

第十章美洲皮肤T细胞淋巴瘤市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区皮肤T细胞淋巴瘤市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲皮肤T细胞淋巴瘤市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FDA核准创新滤泡性淋巴瘤治疗组合
    • FDA核准sokelitinib 作为治疗 T 细胞淋巴瘤的孤儿药
    • 嵌合体 Therapeutics 创新 CTCL 治疗获得 FDA 快速通道认证
  • 战略分析和建议

公司名单

  • 4SC AG
  • Allos Therapeutics, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Bausch Health Companies Inc.
  • Bristol Myers Squibb
  • Corvus Pharmaceuticals, Inc.
  • Eisai Co., Ltd.
  • Elorac, Inc.
  • Helsinn Healthcare SA
  • Incyte Corporation
  • Kyowa Kirin Co., Ltd.
  • Merck & Co. Inc.
  • Mundipharma International Limited
  • PharmaMar SA
  • Seattle Genetics, Inc.
  • Soligenix, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-CB04E05661A6

The Cutaneous T-Cell-Lymphoma Market was valued at USD 416.77 million in 2023, expected to reach USD 432.44 million in 2024, and is projected to grow at a CAGR of 3.91%, to USD 545.49 million by 2030.

Cutaneous T-Cell Lymphoma (CTCL) refers to a rare type of non-Hodgkin's lymphoma that primarily affects the skin, characterized by an uncontrolled proliferation of T-cells. It encompasses various forms, with mycosis fungoides and Sezary syndrome being the most prevalent. The necessity to study this market arises from the complex biological nature of CTCL, which demands innovative diagnostic and treatment approaches. This research informs the development of novel therapies, improved diagnostics, and aids healthcare providers in optimizing patient care. The application of market insights extends to pharmaceutical companies, research institutions, and clinical settings, aiming to refine treatment protocols and create economically viable medical solutions. The end-use scope includes healthcare facilities, research laboratories, and educational institutions focusing on rare cancer advancements. Market growth is primarily driven by advancements in biologics, monoclonal antibodies, and the increasing prevalence of CTCL. Furthermore, rising awareness and improved healthcare infrastructure strengthen the market trajectory. Key opportunities exist in developing targeted therapies and personalized medicine, given the heterogeneity of the disease, and leveraging government support for orphan drug development to accelerate market entry. Recommendations include investing in biomarker research for early detection and pursuing strategic collaborations for innovative therapeutic pipeline development. However, market growth faces limitations like high treatment costs and limited patient populations, which can slow investment returns. Complexity in differential diagnosis and therapeutic resistance also poses significant challenges. Overcoming these hurdles requires a focus on precision medicine and adaptive clinical trial designs. Innovative areas include harnessing AI for predictive analytics, exploring gene therapy prospects, and utilizing real-world evidence in clinical trial settings for CTCL. The nature of this market is niche but steadily expanding, necessitating continuous research and an interdisciplinary approach to address unmet medical needs effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 416.77 million
Estimated Year [2024] USD 432.44 million
Forecast Year [2030] USD 545.49 million
CAGR (%) 3.91%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cutaneous T-Cell-Lymphoma Market

The Cutaneous T-Cell-Lymphoma Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence and awareness toward cutaneous t-cell lymphoma
    • Supportive regulatory policies for fast-track approval processes and incentives
  • Market Restraints
    • High cost of treatment, along with misdiagnosis and delayed diagnosis
  • Market Opportunities
    • Expansion of clinical trials and collaborative research initiatives
    • Rising developments in targeted therapies and immunotherapies
  • Market Challenges
    • Technical and performance issues associated with treatments

Porter's Five Forces: A Strategic Tool for Navigating the Cutaneous T-Cell-Lymphoma Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cutaneous T-Cell-Lymphoma Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cutaneous T-Cell-Lymphoma Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cutaneous T-Cell-Lymphoma Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cutaneous T-Cell-Lymphoma Market

A detailed market share analysis in the Cutaneous T-Cell-Lymphoma Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cutaneous T-Cell-Lymphoma Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cutaneous T-Cell-Lymphoma Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cutaneous T-Cell-Lymphoma Market

A strategic analysis of the Cutaneous T-Cell-Lymphoma Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cutaneous T-Cell-Lymphoma Market, highlighting leading vendors and their innovative profiles. These include 4SC AG, Allos Therapeutics, Inc., Amgen Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Bristol Myers Squibb, Corvus Pharmaceuticals, Inc., Eisai Co., Ltd., Elorac, Inc., Helsinn Healthcare SA, Incyte Corporation, Kyowa Kirin Co., Ltd., Merck & Co. Inc., Mundipharma International Limited, PharmaMar SA, Seattle Genetics, Inc., Soligenix, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Cutaneous T-Cell-Lymphoma Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Mycosis Fungoides and Sezary Syndrome.
  • Based on Treatment, market is studied across Biological Therapies, Phototherapy, Radiation Therapy, and Topical Therapies.
  • Based on Product, market is studied across Imaging Technology, Molecular Diagnostics, Phototherapy Equipment, and Treatment Drugs. The Treatment Drugs is further studied across Chemotherapeutics, Immunomodulators, and Targeted Therapy.
  • Based on End-User, market is studied across Ambulatory Surgery Centers, Dermatology Clinics, Homecare Settings, Hospitals, and Research Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence and awareness toward cutaneous t-cell lymphoma
      • 5.1.1.2. Supportive regulatory policies for fast-track approval processes and incentives
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment, along with misdiagnosis and delayed diagnosis
    • 5.1.3. Opportunities
      • 5.1.3.1. Expansion of clinical trials and collaborative research initiatives
      • 5.1.3.2. Rising developments in targeted therapies and immunotherapies
    • 5.1.4. Challenges
      • 5.1.4.1. Technical and performance issues associated with treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Indication: Burgeoning cases of mycosis fungoides allow for a range of both localized and systemic treatments
    • 5.2.2. End-User: Evolving usage of clinics offering considerable expertise in specific treatments and personalized care for CTCL
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cutaneous T-Cell-Lymphoma Market, by Indication

  • 6.1. Introduction
  • 6.2. Mycosis Fungoides
  • 6.3. Sezary Syndrome

7. Cutaneous T-Cell-Lymphoma Market, by Treatment

  • 7.1. Introduction
  • 7.2. Biological Therapies
  • 7.3. Phototherapy
  • 7.4. Radiation Therapy
  • 7.5. Topical Therapies

8. Cutaneous T-Cell-Lymphoma Market, by Product

  • 8.1. Introduction
  • 8.2. Imaging Technology
  • 8.3. Molecular Diagnostics
  • 8.4. Phototherapy Equipment
  • 8.5. Treatment Drugs
    • 8.5.1. Chemotherapeutics
    • 8.5.2. Immunomodulators
    • 8.5.3. Targeted Therapy

9. Cutaneous T-Cell-Lymphoma Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgery Centers
  • 9.3. Dermatology Clinics
  • 9.4. Homecare Settings
  • 9.5. Hospitals
  • 9.6. Research Centers

10. Americas Cutaneous T-Cell-Lymphoma Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cutaneous T-Cell-Lymphoma Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cutaneous T-Cell-Lymphoma Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Granted Approval of Innovative Follicular Lymphoma Treatment Combination
    • 13.3.2. FDA Endorses Soquelitinib for T-Cell Lymphoma with Orphan Drug Designation
    • 13.3.3. Kymera Therapeutics Granted FDA Fast Track Status for Innovative CTCL Treatment
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 4SC AG
  • 2. Allos Therapeutics, Inc.
  • 3. Amgen Inc.
  • 4. Astellas Pharma Inc.
  • 5. Bausch Health Companies Inc.
  • 6. Bristol Myers Squibb
  • 7. Corvus Pharmaceuticals, Inc.
  • 8. Eisai Co., Ltd.
  • 9. Elorac, Inc.
  • 10. Helsinn Healthcare SA
  • 11. Incyte Corporation
  • 12. Kyowa Kirin Co., Ltd.
  • 13. Merck & Co. Inc.
  • 14. Mundipharma International Limited
  • 15. PharmaMar SA
  • 16. Seattle Genetics, Inc.
  • 17. Soligenix, Inc.
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. CUTANEOUS T-CELL-LYMPHOMA MARKET RESEARCH PROCESS
  • FIGURE 2. CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CUTANEOUS T-CELL-LYMPHOMA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CUTANEOUS T-CELL-LYMPHOMA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CUTANEOUS T-CELL-LYMPHOMA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CUTANEOUS T-CELL-LYMPHOMA MARKET DYNAMICS
  • TABLE 7. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY MYCOSIS FUNGOIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY SEZARY SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY BIOLOGICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PHOTOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TOPICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY IMAGING TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PHOTOTHERAPY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY CHEMOTHERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 239. CUTANEOUS T-CELL-LYMPHOMA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 240. CUTANEOUS T-CELL-LYMPHOMA MARKET, FPNV POSITIONING MATRIX, 2023